The Upfront Shock

The Upfront Shock

Doximity did not glide into its slowdown. Fiscal 2026 ran hot for two quarters — revenue up 15% then 23%, with the full-year guide raised twice — and then broke in the back half, printing 10% and 5% growth. The break has a datable cause: a wave of drug-pricing agreements that landed on Doximity's largest pharmaceutical customers at the exact week they set annual budgets. The FY2027 selling season will show whether that is a timing shock or the onset of a lower run-rate.

A hot first half, a cold second half

Through September, Doximity looked like it was reaccelerating. First-quarter revenue was $145.9 million, up 15% and above the top of guidance; net revenue retention held at 118% [1]. Management raised the full-year outlook to $628–636 million (11% growth) and told investors it had "not yet seen any slowdown in our business" [2]. The second quarter was stronger still: $168.5 million, up 23% and a 7% beat, prompting a second guidance raise to $640–646 million (13% growth) [3].

The 23% print flattered the trend. Doximity's newer multi-module "integrated" programs — which start in January and let clients add spend evenly through the year — reached over 40% of second-quarter bookings, against less than 5% a year earlier, pulling upsell dollars forward that would historically have landed later. Management said as much, warning it did "not expect as large of a step-up between Q2 and Q3 as we've seen in prior years" [4]. The cleaner read is the annual one: calendar-2025 growth of roughly 15%, about twice the digital-advertising market.

Then the second half arrived. Third-quarter revenue grew 10% to $185.1 million [5]; the fourth quarter grew 5% to $145.4 million, closing the year at $645 million, up 13% [6]. A business that had beaten and raised its way through the summer was guiding to low-single-digit growth by winter.

Source: quarterly revenue as reported, Q1–Q4 FY2026 earnings calls [7], [8], [9], [10]; prior-year quarters derived from reported financials.

Fiscal 2025 stayed inside a 17–25% band all four quarters. Fiscal 2026 held that band through Q2, then fell to a level the company had not seen as a public entity. The question is what happened between the two.

What broke in the upfront

Doximity's growth is set once a year, in the "upfront" — the fourth-calendar-quarter selling season when pharmaceutical brands commit annual budgets, most of them signed by December 31. That is the window that failed.

Between late December and early January, 16 of Doximity's top 20 pharmaceutical customers signed "most favored nation" pricing agreements with the White House covering tariffs and drug pricing [11]. Arriving at the worst possible moment, the uncertainty hit the upfront two ways: customers deployed a lower share of their annual budgets upfront, leaving funds unreleased, and deals that would normally have closed by year-end slipped into Doximity's fiscal fourth quarter [12]. Management cut the fourth-quarter guide to $143–144 million, 4% growth, and said calendar 2026 was "off to a slower start than usual" [13].

The same disclosure carries a number that cuts the other way. If demand had been destroyed, the pushed deals would have vanished; instead they reappeared. Doximity's January pharmaceutical bookings growth was, in management's words, "the best we've seen since going public" [14]. The upfront was disrupted in timing, not erased in demand — a distinction that weighs toward the cyclical reading of the slowdown, provided the delayed dollars are actually spent later in the year rather than cancelled.

Retention tells the other side

The bookings tell is real, but so is a slower signal underneath it. Doximity's growth reset from 20% to a guided 4% reached its biggest, most committed customers — top-20 net revenue retention fell from 119% to 114% and the over-$500k cohort's growth halved to 6% — so the deceleration is not only in the marginal spend a cyclical rebound would restore. Net revenue retention — the rate at which existing customers grow their spend — fell every quarter of fiscal 2026: total retention slid from 118% to 109%, and the $500,000-plus customer count, roughly 83% of revenue, actually ticked down between Q3 and Q4.

Source: trailing-twelve-month net revenue retention and customer counts, Q1–Q4 FY2026 earnings calls [15], [16], [17], [18]; top-20 rate not disclosed in Q2.

Retention above 100% still means the installed base expanded; a 109% rate is not contraction. But the direction is the point. A cyclical air-pocket in a single upfront should leave the biggest, most committed clients intact and show up mostly in discretionary marginal spend. That the top-20 rate also fell nine points from its peak — resolving a question earlier chapters left open — says the pressure reached the accounts that anchor the business, and is harder to wave off as one bad December.

The fiscal 2027 test

Management's own framing turns the near-term tape into a falsifiable test. The FY2027 guide is $664–676 million, 4% growth, against a digital-advertising market it now expects to grow "at or below 5%" — the first year in memory Doximity guides to roughly the market rate rather than twice it. Entering the year it had 65% of its subscription-revenue guidance booked, in line with its three-year average, but "with more moderate growth" embedded [19]. Asked directly how it would reassure investors that pharma is not simply learning to do more with less, management conceded this year would be "in line with the market, maybe slight outperformance" [20].

Two dynamics decide whether that 4% is a floor or a trough. The first is behavioral: several top-20 clients have moved from annual commitments to three- and six-month buys, which cuts Doximity's visibility even as it lets the company charge higher prices for shorter commitments [21]. If the shift is a durable response to policy noise, the guided-in caution persists; if it is the noise itself passing, the annual commitments return. The "do more with less" worry management was pressed on is the structural version of this same question [22].

The second is the unbooked 35%, which rests on two sources of back-half spend. Management expects the budgets held back during the disrupted upfront to be released later in the year, and it has, for the first time, a commercial product to sell against them: AI Search, launched in late April, with the first few deals already closed with top-20 pharma manufacturers, though it carries minimal FY2027 revenue and ramps only in the fiscal back half [23], [24]. Management's stated benchmark, repeated across two calls, is to "exit the calendar year as a double-digit grower once again" [25].

That benchmark is a datable test. If the fiscal back half — the October-to-March quarters, where the delayed budgets and the AI-Search ramp both land — returns to double-digit growth, the upfront break was a timing shock and the 4% guide was conservatism about the release of held-back dollars. If those quarters instead settle near the guided rate, the shorter commitments and the softer retention are the run-rate, and 4% is closer to what a near-universal network can extract from a pharmaceutical budget that is no longer expanding. The bookings evidence points to the first; the retention trend keeps the second live. On current evidence the timing explanation is better supported, but it is conditional on money the company has not yet collected, and the CY2026 upsell season is where it is confirmed or denied.